Treatment sequencing for CRPC—what do we know?
Authors:
- 4 March 2014
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Urology
- Vol. 11 (4) , 189-190
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine AgentsEuropean Urology, 2014
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2014
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and AbirateroneEuropean Urology, 2014
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?Annals of Oncology, 2012
- A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!International Journal of Biological Sciences, 2011
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerCancer Research, 2010
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004